Pharmafile Logo

Hospira

- PMLiVE

Israel finds a ‘probable link’ between Pfizer vaccine and myocarditis cases

Reported cases increased following the second dose of the mRNA-based COVID-19 vaccine

- PMLiVE

First NHS patient treated with Novartis’ SMA gene therapy Zolgensma

Novartis and NHS England reached a landmark deal for the gene therapy earlier this year

- PMLiVE

EMA authorises Pfizer/BioNTech’s COVID-19 vaccine for children aged 12 to 15

Clinical trial data recently showed that the vaccine is safe and effective in individuals in this age group

- PMLiVE

Novartis, Molecular Partners launch global study of novel COVID-19 drug

Initial positive phase 1 study results found that the drug was safe and well tolerated, with no significant adverse events reported

- PMLiVE

AZ, Pfizer/BioNTech COVID-19 vaccines ‘highly effective’ against Indian variant

UK study finds vaccines are likely to be effective in preventing hospitalisation/death

- PMLiVE

Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab

Trial will enrol 600 adults, aged 65 and older, from the phase 3 Pfizer/BioNTech COVID-19 vaccine trial

- PMLiVE

BeiGene, Novartis’ tislelizumab report promising topline results in nasopharyngeal cancer

In 2018, 46.9% of global cases of nasopharyngeal cancer occurred in China

- PMLiVE

Sandoz reveals antibiotic manufacturing expansion plans in Europe

Builds on company's previous commitments to drive the long-term future of integrated antibiotics manufacturing in Europe

- PMLiVE

US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case

Amgen will retain market exclusivity on blockbuster arthritis drug until 2029

- PMLiVE

Developers of COVID-19 vaccines and therapeutics highlight continued need for treatments

Continued need for vaccines/treatments 'likely' as world moves into the next phase of the pandemic

- PMLiVE

Pfizer asks UK’s MHRA to approve its COVID-19 vaccine in adolescents

The vaccine has been authorised in the US for 12- to 15-year-olds

- PMLiVE

Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’

Company says removing IP protections would make it ‘harder’ to make vaccines in the short term

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links